[{"id":"f0aa223d-45fe-469e-a692-cb8949633296","acronym":"NAVIGATE","url":"https://clinicaltrials.gov/study/NCT02576431","created_at":"2021-01-17T17:25:20.190Z","updated_at":"2025-02-25T15:42:38.245Z","phase":"Phase 2","brief_title":"A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors","source_id_and_acronym":"NCT02576431 - NAVIGATE","lead_sponsor":"Bayer","biomarkers":" NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 09/30/2015","start_date":" 09/30/2015","primary_txt":" Primary completion: 07/20/2025","primary_completion_date":" 07/20/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-10"},{"id":"245c1786-d5c4-49a7-8439-75f183f39949","acronym":"","url":"https://clinicaltrials.gov/study/NCT05783323","created_at":"2023-03-24T16:04:14.237Z","updated_at":"2025-02-25T17:26:04.484Z","phase":"Phase 2","brief_title":"Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer","source_id_and_acronym":"NCT05783323","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 02/14/2024","start_date":" 02/14/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2024-11-12"},{"id":"41b01b41-ccaf-44d0-9901-ee4360f0dfd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828303","created_at":"2023-04-25T14:03:37.911Z","updated_at":"2024-07-02T16:35:10.118Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05828303","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib) • metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/28/2024","start_date":" 06/28/2024","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-04-11"},{"id":"1cdd60d2-369d-4e42-890d-606bbb974c28","acronym":"","url":"https://clinicaltrials.gov/study/NCT06010342","created_at":"2023-08-24T16:11:42.524Z","updated_at":"2024-07-02T16:35:10.443Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients","source_id_and_acronym":"NCT06010342","lead_sponsor":"Teligene US","biomarkers":" NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TL118"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-10"},{"id":"dcc86dfa-5f1f-487e-97bd-3b553b98917f","acronym":"STARTRK-NG","url":"https://clinicaltrials.gov/study/NCT02650401","created_at":"2021-01-18T12:54:05.938Z","updated_at":"2024-07-02T16:35:12.285Z","phase":"Phase 1/2","brief_title":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","source_id_and_acronym":"NCT02650401 - STARTRK-NG","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 05/03/2016","start_date":" 05/03/2016","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2024-03-29"},{"id":"9eaee900-c56a-440b-bf3e-d9e5c14d97d5","acronym":"ADVL1823","url":"https://clinicaltrials.gov/study/NCT03834961","created_at":"2021-01-18T18:56:06.238Z","updated_at":"2024-07-02T16:35:13.156Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia","source_id_and_acronym":"NCT03834961 - ADVL1823","lead_sponsor":"Children's Oncology Group","biomarkers":" NTRK1 • NTRK3 • NTRK2 • ETV6","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2 • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/25/2019","start_date":" 10/25/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-03-22"},{"id":"78482e2a-4e36-4c51-a81b-de4897029fc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05004116","created_at":"2021-08-13T12:53:24.897Z","updated_at":"2024-07-02T16:35:15.181Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer","source_id_and_acronym":"NCT05004116","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-03-12"},{"id":"ad35a256-b12d-4264-8406-c8f148399527","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828277","created_at":"2023-04-25T14:03:37.480Z","updated_at":"2024-07-02T16:35:35.756Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients","source_id_and_acronym":"NCT05828277","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2 • AFP • NTRK","pipe":" | ","alterations":" NTRK1 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2 • AFP • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/28/2022","start_date":" 07/28/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-26"},{"id":"b9d29ac1-22f0-48b2-a031-d017175875c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05914116","created_at":"2023-06-22T19:11:45.274Z","updated_at":"2024-07-02T16:35:37.381Z","phase":"Phase 1/2","brief_title":"A Study of DB-1311 in Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05914116","lead_sponsor":"DualityBio Inc.","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK1 • NTRK3 • NTRK2 • CD276","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12 • NTRK1 mutation • NTRK3 mutation","tags":["EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK1 • NTRK3 • NTRK2 • CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12 • NTRK1 mutation • NTRK3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT324"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 09/05/2023","start_date":" 09/05/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2023-09-12"},{"id":"3e913d99-df53-4faa-8b4e-40650b3c220b","acronym":"RNASARC","url":"https://clinicaltrials.gov/study/NCT03375437","created_at":"2021-01-18T16:39:34.592Z","updated_at":"2024-07-02T16:35:51.030Z","phase":"","brief_title":"RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.","source_id_and_acronym":"NCT03375437 - RNASARC","lead_sponsor":"Centre Leon Berard","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK fusion • ROS1 fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK fusion • ROS1 fusion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 376","initiation":"Initiation: 02/15/2018","start_date":" 02/15/2018","primary_txt":" Primary completion: 02/15/2024","primary_completion_date":" 02/15/2024","study_txt":" Completion: 01/15/2025","study_completion_date":" 01/15/2025","last_update_posted":"2023-04-10"},{"id":"c81fb89a-a657-47dd-9b13-7d83c2b9a7e0","acronym":"APT-CUBE","url":"https://clinicaltrials.gov/study/NCT05473156","created_at":"2022-07-25T20:54:40.231Z","updated_at":"2024-07-02T16:35:56.496Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies","source_id_and_acronym":"NCT05473156 - APT-CUBE","lead_sponsor":"AP Biosciences Inc.","biomarkers":" BRAF • MET • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • MET mutation • RET rearrangement • NTRK1 mutation • NTRK3 mutation","tags":["BRAF • MET • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • MET mutation • RET rearrangement • NTRK1 mutation • NTRK3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AP203"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-02-03"},{"id":"25c64f33-801c-46c5-8cbf-381cc597fe7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206931","created_at":"2021-01-18T15:48:28.443Z","updated_at":"2025-02-25T17:09:47.148Z","phase":"","brief_title":"Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion","source_id_and_acronym":"NCT03206931","lead_sponsor":"Bayer","biomarkers":" NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e selitrectinib (BAY 2731954)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2021-09-16"},{"id":"455bb5f8-dfe6-4827-a577-3f71d18ec8ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT04617054","created_at":"2021-01-19T20:33:44.655Z","updated_at":"2024-07-02T16:36:28.868Z","phase":"Phase 2","brief_title":"Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene","source_id_and_acronym":"NCT04617054","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibtrozi (taletrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2021-06-21"}]